Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWARD PEARSON

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1801188172
CMS profile
1380771
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$202,255.81

233 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 233 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWARD PEARSON

NPI 1801188172 · CMS profile ID 1380771

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 233 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801188172?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWARD PEARSON, NPI 1801188172, CMS profile ID 1380771. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 233 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801188172?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EDWARD PEARSON, NPI 1801188172, CMS profile ID 1380771. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 233 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801188172?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EDWARD PEARSON, NPI 1801188172, CMS profile ID 1380771, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 233 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1801188172?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

233 matching records · $202,255.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 233 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 233.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genmab U.S., Inc. $124.9909/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826190 CMS
GENZYME CORPORATION $46.1609/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139860318 CMS
Genmab U.S., Inc. $10.0009/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826184 CMS
Genmab U.S., Inc. $71.9009/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826186 CMS
Genmab U.S., Inc. $3,325.0009/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826192 CMS
ABBVIE INC. $13.2409/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105222597 CMS
ADC Therapeutics America, Inc. $23.4309/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121188818 CMS
GENZYME CORPORATION $535.0009/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139860324 CMS
Genmab U.S., Inc. $30.1309/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826180 CMS
PharmaEssentia USA Corporation $1,675.0009/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137306107 CMS
Genmab U.S., Inc. $692.1509/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826196 CMS
Genmab U.S., Inc. $9.0009/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826198 CMS
Genmab U.S., Inc. $3,325.0009/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826204 CMS
Genmab U.S., Inc. $33.0009/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826218 CMS
Genmab U.S., Inc. $71.5409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826182 CMS
Blueprint Medicines Corporation $3,276.0009/04/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147445816 CMS
ADC Therapeutics America, Inc. $22.0208/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121188810 CMS
Blueprint Medicines Corporation $1,008.0008/28/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147445820 CMS
Rigel Pharmaceuticals, Inc. $1,463.0008/22/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145204866 CMS
GENZYME CORPORATION $120.6108/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139860332 CMS
GENZYME CORPORATION $3,852.0008/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139860334 CMS
Incyte Corporation $1,100.0008/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141201173 CMS
Genmab U.S., Inc. $26.7508/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826178 CMS
Blueprint Medicines Corporation $936.0008/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147445656 CMS
Blueprint Medicines Corporation $89.8008/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147445814 CMS
ABBVIE INC. $13.9008/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105222593 CMS
Celgene Corporation $300.0008/02/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101172488 CMS
Karyopharm Therapeutics Inc. $19.7707/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145529381 CMS
ABBVIE INC. $3,325.0007/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105222589 CMS
Incyte Corporation $23.1507/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141281234 CMS
Incyte Corporation $1,100.0007/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141191027 CMS
Genmab U.S., Inc. $536.3407/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826194 CMS
Merck Sharp & Dohme LLC $32.7907/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141822973 CMS
SERVIER PHARMACEUTICALS LLC $1,260.0007/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147259332 CMS
Blueprint Medicines Corporation $1,008.0007/12/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147445818 CMS
GENZYME CORPORATION $3,852.0007/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139860352 CMS
Kite Pharma, Inc. $25.9907/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128613357 CMS
ABBVIE INC. $874.9007/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105222585 CMS
Incyte Corporation $1.0407/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141244892 CMS
Incyte Corporation $22.2407/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141280300 CMS
GENZYME CORPORATION $133.4606/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139860362 CMS
GENZYME CORPORATION $31.0206/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139860364 CMS
GENZYME CORPORATION $6,420.0006/28/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139860366 CMS
SERVIER PHARMACEUTICALS LLC $96.0306/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147259328 CMS
SERVIER PHARMACEUTICALS LLC $855.9106/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147259330 CMS
ABBVIE INC. $3,325.0006/25/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105222581 CMS
SERVIER PHARMACEUTICALS LLC $1,260.0006/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147259326 CMS
GlaxoSmithKline, LLC. $3,900.0006/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116389352 CMS
GlaxoSmithKline, LLC. $3,900.0006/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116581291 CMS
Incyte Corporation $1,650.0006/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141322987 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $15,180.16 44
PY2020 $55,393.96 66
PY2021 $95,591.91 124
PY2022 $144,635.92 169
PY2023 $206,621.23 289
PY2024 $202,255.81 233
PY2025 $180,763.92 182

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $138,839.30 39
PY2024 Recipient $330.00 1
PY2024 Principal investigator $331,332.46 37
PY2023 Principal investigator $147,240.98 33
PY2022 Principal investigator $93,843.09 17
PY2021 Principal investigator $131,115.47 21
PY2020 Principal investigator $72,783.48 15
PY2019 Principal investigator $107,414.93 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $250.00 12/18/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578321
Principal investigator 1 Genentech, Inc. $1,600.00 12/12/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578330
Principal investigator 1 Genentech, Inc. $3,200.00 12/12/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578336
Principal investigator 1 Genentech, Inc. $101.00 12/11/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578239
Principal investigator 1 Genentech, Inc. $200.00 12/04/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578326
Principal investigator 1 Genentech, Inc. $350.00 11/20/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578317
Principal investigator 1 Genentech, Inc. $4,374.00 11/19/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578313
Principal investigator 1 Genentech, Inc. $2,900.00 11/04/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578309
Principal investigator 1 Genentech, Inc. $800.00 10/29/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578305
Principal investigator 1 Genentech, Inc. $495.00 10/14/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578251
Principal investigator 1 Genentech, Inc. $10,946.00 10/14/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578254
Principal investigator 1 Genentech, Inc. $100.00 10/14/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578259
Principal investigator 1 Genentech, Inc. $3,416.00 10/14/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578263
Principal investigator 1 Genentech, Inc. $11,677.00 10/14/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578266
Principal investigator 1 PFIZER INC. $16,927.00 10/06/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228713248
Principal investigator 1 Genentech, Inc. $100.00 09/24/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578288
Principal investigator 1 Genentech, Inc. $568.00 09/18/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578297
Principal investigator 1 PFIZER INC. $387.10 09/15/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228824614
Principal investigator 1 PFIZER INC. $191.10 09/08/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228824619
Principal investigator 1 Genentech, Inc. $6,025.00 08/28/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578292
Principal investigator 1 Genentech, Inc. $600.00 08/21/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578301
Principal investigator 1 PFIZER INC. $16,927.00 08/18/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228824625
Principal investigator 1 PFIZER INC. $2,053.20 08/04/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228834282
Principal investigator 1 PFIZER INC. $2,368.00 08/04/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228835026
Principal investigator 1 Genentech, Inc. $8,958.00 07/25/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578275
Principal investigator 1 Genentech, Inc. $1,145.30 07/22/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578284
Principal investigator 1 Genentech, Inc. $11,202.00 07/07/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578279
Principal investigator 1 Karyopharm Therapeutics Inc. $1,125.00 07/03/2025 Non-covered Recipient Entity
USOR: TX Oncology Fort Worth
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1246666790
Principal investigator 1 Genentech, Inc. $2,187.00 06/02/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578242
Principal investigator 1 PFIZER INC. $624.20 05/19/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228842857
Principal investigator 1 PFIZER INC. $824.20 05/12/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228844042
Principal investigator 1 Genentech, Inc. $2,462.00 04/25/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578271
Principal investigator 1 PFIZER INC. $537.10 04/21/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228845862
Principal investigator 1 PFIZER INC. $87.10 03/24/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228845284
Principal investigator 1 PFIZER INC. $455.00 03/24/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228845869
Principal investigator 1 PFIZER INC. $600.00 03/24/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228846673
Principal investigator 1 Genentech, Inc. $1,250.00 02/20/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211578246
Principal investigator 1 PFIZER INC. $16,927.00 02/18/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228845540
Principal investigator 1 PFIZER INC. $3,900.00 01/06/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228845354